ViroGates is listed on Nasdaq OMX First North in Denmark
Tue Jun 26 2018
ViroGates has achieved a significant milestone – the completion of its successful initial public offering (IPO) of new shares. Investors’ response was overwhelming, with the IPO being oversubscribed by a remarkable 141%. This accomplishment marks a substantial step for the company as it lists on Denmark’s Nasdaq OMX First North.
The company’s success is attributed to its strategic issuance of newly issued shares, ranging from a minimum of 659,341 to a maximum of 824,175. Each share was priced at DKK 91. All shares have been subscribed, resulting in the issuance of 824,175 shares and gross proceeds of DKK 75.0 million. These funds will be crucial in shaping the company’s future initiatives.
The allocation of funds is well-planned. A significant portion will be directed toward intensifying the commercial rollout of ViroGates’ cutting-edge products. This approach solidifies the company’s market position and meets the needs of healthcare professionals and patients.
Additionally, the successful IPO will strengthen ongoing efforts in product development, clinical documentation, and global patent coverage. These areas uphold ViroGates’ reputation for innovation and reliability in medical diagnostics.
ViroGates’ shares will be traded under the “VIRO” symbol (ISIN: DK0061030574) starting June 26, 2018. This step opens opportunities for investors and stakeholders to engage with the company’s growth journey.
The IPO’s success underscores investors’ trust in the company’s vision. As ViroGates takes its place on Nasdaq OMX First North, it is poised to make strides in medical diagnostics, patient care, and the global healthcare landscape. Stay tuned for updates on ViroGates’ exciting journey ahead.
More information to be found here; Investor – Announcements
